LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes

被引:49
作者
Eliasson, B. [1 ]
Gudbjoernsdottir, S. [1 ]
Zethelius, B. [2 ]
Eeg-Olofsson, K. [1 ]
Cederholm, J. [3 ]
机构
[1] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Med, Gothenburg, Sweden
[2] Uppsala Univ, Dept Publ Hlth & Caring Sci Geriatr, Uppsala, Sweden
[3] Uppsala Univ, Dept Publ Hlth & Caring Sci Family Med & Prevent, Uppsala, Sweden
关键词
Diabetes mellitus; lipoproteins; LDL-cholesterol; non-HDL-cholesterol; coronary heart disease; human; epidemiology; DENSITY-LIPOPROTEIN CHOLESTEROL; DIFFERENT LIPID MEASURES; SUBCLINICAL ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASES; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; MEN; ATORVASTATIN; PREDICTION; UTILITY;
D O I
10.1177/2047487313494292
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We assessed the association between different blood lipid measures and risk of fatal/nonfatal coronary heart disease (CHD), which has been less analysed previously in type 2 diabetes. Design, methods Observational study of 46,786 patients with type 2 diabetes, aged 30-70 years, from the Swedish National Diabetes Register, followed for a mean of 5.8 years until 2009. Baseline and updated mean low-density lipoprotein (LDL)-, high-density lipoprotein (HDL)-, non-HDL-cholesterol, and non-HDL-to-HDL-cholesterol ratio were measured. Results Hazard ratios (HR) for CHD with quartiles 2-4 of baseline lipid measures, with lowest quartile 1 as reference: 1.03-1.29-1.63 for LDL; 1.23-1.41-1.95 for non-HDL; 1.29-1.39-1.57 for HDL; and 1.31-1.67-2.01 for non-HDL:HDL, all p<0.001 except for quartile 2 of LDL, when adjusted for clinical characteristics and nonlipid risk factors. A similar picture was seen with updated mean values. Splines with absolute 6-year CHD rates in a Cox model showed decreasing rates only down to around 3mmol/l for LDL, with linearly decreasing rates to the lowest level of non-HDL:HDL. Non-HDL and HDL were independent additive risk factors for CHD risk. HRs per 1SD continuous decrease in baseline or updated mean HDL were 1.14-1.17 when fully adjusted as above, and 1.08-1.13 when also adjusted for non-HDL (p<0.001). HRs were 1.13-1.16 adjusted for LDL, and 1.22-1.26 adjusted for total cholesterol and triglycerides (p<0.001). Splines showed progressively increasing 6-year CHD rates with lower HDL down to 0.5mmol/l. Conclusions This study suggests that lower levels of non-HDL:HDL are a better risk marker for CHD than LDL-cholesterol below 3mmol/l.
引用
收藏
页码:1420 / 1428
页数:9
相关论文
共 41 条
[1]  
[Anonymous], 2013, Diabetes Care, V36, pS4
[2]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[3]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[4]   Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].
Boden, William E. ;
Probstfield, Jeffrey L. ;
Anderson, Todd ;
Chaitman, Bernard R. ;
Desvignes-Nickens, Patrice ;
Koprowicz, Kent ;
McBride, Ruth ;
Teo, Koon ;
Weintraub, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267
[5]   Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation [J].
Brunzell, John D. ;
Davidson, Michael ;
Furberg, Curt D. ;
Goldberg, Ronald B. ;
Howard, Barbara V. ;
Stein, James H. ;
Witztum, Joseph L. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (15) :1512-1524
[6]   INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].
CASTELLI, WP ;
GARRISON, RJ ;
WILSON, PWF ;
ABBOTT, RD ;
KALOUSDIAN, S ;
KANNEL, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838
[7]   Different methods to present the effect of blood pressure on cardiovascular diseases by Cox regression [J].
Cederholm, Jan ;
Zethelius, Bjorn ;
Eliasson, Bjorn ;
Gudbjornsdottir, Soffia ;
Nilsson, Peter M. .
JOURNAL OF HYPERTENSION, 2012, 30 (01) :235-237
[8]   Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol [J].
deGoma, Emil M. ;
Leeper, Nicholas J. ;
Heidenreich, Paul A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (01) :49-55
[9]   Clinical Usefulness of Different Lipid Measures for Prediction of Coronary Heart Disease in Type 2 Diabetes A report from the Swedish National Diabetes Register [J].
Eliasson, Bjorn ;
Cederholm, Jan ;
Eeg-Olofsson, Katarina ;
Svensson, Anne-Marie ;
Zethelius, Bjorn ;
Gudbjornsdottir, Soffia .
DIABETES CARE, 2011, 34 (09) :2095-2100
[10]   Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus-An Observational Study from the Swedish National Diabetes Register [J].
Eliasson, Bjorn ;
Svensson, Ann-Marie ;
Miftaraj, Mervete ;
Jonasson, Junmei Miao ;
Eeg-Olofsson, Katarina ;
Sundell, Karolina Andersson ;
Gudbjornsdottir, Soffia .
PLOS ONE, 2011, 6 (04)